Emerald Acquisition’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Emerald Acquisition’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$535K	Buy	+39,056	New	+$392K	﹤0.01%	2415

Other funds holding ARIA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Emerald Acquisition's ARIA Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Ariad Pharmaceuticals Inc (ARIA) in Q3 2016: 39,056 shares worth $535K. The stake represents ﹤0.01% of the portfolio and ranks #2415 among its holdings.

202 funds tracked by Wall St. Rank hold ARIA as of Q3 2016.

Emerald Acquisition held 39,056 shares of Ariad Pharmaceuticals Inc worth $535K as of Q3 2016.
Ariad Pharmaceuticals Inc was a new Emerald Acquisition position in Q3 2016.
Ariad Pharmaceuticals Inc made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2415 holding.
202 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.